A pilot RCT of a structured diabetes education programme with episodic rtCGM use in a non-insulin-treated type 2 diabetes population demonstrated no significant HbA1c improvement compared with SMBG [28], while an RCT of intermittent short-term use of rtCGM compared with SMBG found a 0.64 pp (6 mmol/mol) HbA1c reduction (p=0.014) [29]. The gene discussed is INS; the disease is diabetes mellitus.